Every Form 4 that Tango Therapeutics Inc (TNGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TNGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNGX filings page.
Tango Therapeutics, Inc. (TNGX) reported that Crystal Adam, President, R&D, exercised stock options for 27,000 shares of common stock on September 1, 2026 at an exercise price of $5.20 per share and sold 27,000 shares at a weighted average price of $22.367 per share. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 27, 2025. Following the option exercise, Adam held 260,040 stock options directly, which remain outstanding and exercisable through their stated expiration, subject to the vesting schedule.
Tango Therapeutics, Inc. reported that Crystal Adam, President, R&D, exercised stock options to acquire 27,000 shares of common stock at $5.20 per share and, on the same date, sold 27,000 shares in two tranches of 5,267 and 21,733 shares at weighted average prices of $26.7895 and $27.3509 per share. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 27, 2025, and following the option exercise she held 287,040 stock options to purchase common shares.
Tango Therapeutics, Inc. President, R&D Crystal Adam reported an exercise-and-sell transaction in company common stock. She exercised stock options for 27,000 shares at $5.20 per share, then sold a total of 27,000 shares in open-market trades at weighted-average prices around $29–$30.
The filing shows two sale blocks: 7,371 shares at a weighted-average price of $30.2464 and 19,629 shares at $29.3424. After these transactions, Adam directly holds 115,743 shares of common stock. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025, indicating they were scheduled in advance.
Tango Therapeutics director Robert Azelby reported equity awards from the company. He received 5,740 shares of Common Stock in the form of restricted stock units (RSUs), with each RSU representing one future share.
The RSUs will vest in three substantially equal annual installments following the grant date, as long as he remains in continuous service. He was also granted a stock option covering 35,910 shares of Common Stock at an exercise price of $27.97 per share. This option vests in 36 substantially equal monthly installments over three years, subject to continued service, and expires on June 19, 2036. These are compensation-related grants, not open‑market purchases.
Tango Therapeutics director John B. Ketchum received an equity grant consisting of 4,000 restricted stock units and an option for 25,000 shares of Common Stock. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, subject to continued service. The stock option, with a $20.22 exercise price, vests in 12 equal monthly installments beginning July 5, 2026 and expires on June 5, 2036. Following these grants, Ketchum directly holds 24,937 shares of Common Stock.
Tango Therapeutics director Lesley Ann Calhoun received new equity awards, increasing her direct stake in the company. She was granted 4,000 shares of Common Stock in the form of restricted stock units and now directly holds 16,500 Common shares after this award.
She was also granted options to purchase 25,000 shares of Common Stock at an exercise price of $20.2200 per share, expiring on June 5, 2036. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, while the options vest in 12 equal monthly installments starting July 5, 2026, in each case subject to her continuous service.
Tango Therapeutics director Mace Rothenberg reported equity awards in the form of restricted stock units and stock options. The filing shows a grant of 4,000 shares of Common Stock represented by restricted stock units, plus a stock option for 25,000 shares at an exercise price of $20.2200 per share.
The restricted stock units vest in full on the earlier of June 5, 2027 or the next annual meeting of stockholders, subject to continuous service. The option vests in 12 substantially equal monthly installments over one year starting on July 5, 2026 and expires on June 5, 2036. After the stock grant, Rothenberg holds 41,500 shares of Common Stock directly.
Tango Therapeutics director Lee Sung received new equity awards consisting of restricted stock units and stock options. The filing shows a grant of 570 RSUs, each representing one share of common stock, increasing her direct common stock holdings to 22,870 shares after the award.
An additional stock option covering 3,570 shares of common stock was granted with an exercise price of $20.22 per share and an expiration date of June 5, 2036. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, while the option vests in 12 equal monthly installments starting July 5, 2026, in each case contingent on continued service.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an exercise-and-sale transaction in company stock. On June 1, 2026, she exercised 27,000 stock options at $5.20 per share and sold 27,000 common shares in open-market trades at weighted average prices of $22.25 and $23.06 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, she directly holds 115,743 shares of common stock and 341,040 stock options.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an exercise-and-sell transaction in company stock. On May 1, 2026, she exercised 27,000 stock options at an exercise price of $5.20 per share, acquiring the same number of common shares.
That day she made two open-market sales totaling 27,000 common shares: 1,100 shares at a weighted average price of $21.9964 per share and 25,900 shares at a weighted average price of $21.1931 per share. According to a footnote, these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025.
Tango Therapeutics, Inc.’s Chief Financial Officer Matthew Gall received new equity-based compensation. He was granted 40,000 shares of Common Stock in the form of restricted stock units, which represent rights to receive an equal number of shares as they vest over time.
The RSUs vest over three years: 13,200 units on or about May 10, 2027, 13,200 on or about May 10, 2028, and 13,600 on or about May 9, 2029, subject to continued service. He was also granted stock options for 240,000 shares of Common Stock at an exercise price of $20.98 per share, vesting 25% on April 15, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, also contingent on continued service.
Tango Therapeutics director Lee Sung received new equity awards as part of board compensation. On April 29, 2026, Sung was granted 12,300 restricted stock units, each representing one share of common stock. These RSUs vest in three equal annual installments on January 2, 2027, January 2, 2028, and January 2, 2029, contingent on continued board service.
Sung was also granted an option for 5,200 shares of common stock at an exercise price of $22.06 per share. This option vests in 36 substantially equal monthly installments over three years starting January 2, 2026, subject to continued service. Following the grants, Sung holds 22,300 shares of common stock directly and 5,200 stock options, reflecting routine non-employee director compensation rather than open-market trading.
Tango Therapeutics, Inc. President of R&D Crystal Adam exercised stock options to acquire 38,460 shares of common stock at an exercise price of $5.20 per share, then sold 38,460 shares in an open-market transaction at $25.00 per share. Following the sale, she directly holds 112,622 common shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025.
Tango Therapeutics President of R&D Crystal Adam exercised stock options for 27,000 shares of common stock at an exercise price of $5.20 per share and, on the same day, sold 27,000 shares at a weighted-average price of $21.2029 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the sale, Adam directly holds 112,622 shares of Tango Therapeutics common stock.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an option exercise and related stock sale. On March 25, 2026, she exercised stock options to acquire 12,000 shares of common stock at $5.20 per share, then sold 12,000 shares in open‑market transactions at a weighted‑average price of $20.11 per share.
These trades were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on October 27, 2025. After the transactions, she held 112,622 shares of common stock directly and 460,500 stock options, indicating the sale represents a relatively small portion of her overall position.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an open-market sale of 20,251 shares of common stock at $15.00 per share. After this transaction, she directly owned 112,622 shares of Tango Therapeutics common stock.
The sale was executed on March 5, 2026 and is described as an open-market or private transaction. According to a footnote, these trades were carried out under a pre-established Rule 10b5-1 trading plan adopted on October 27, 2025, which automates transactions under preset instructions.
Tango Therapeutics, Inc. reported that Crystal Adam, its President, R&D, sold 54,345 shares of common stock on February 25, 2026. The open-market sale was executed at a weighted average price of $12.7741 per share under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025. Following this transaction, Adam directly owns 132,873 Tango Therapeutics common shares.
Tango Therapeutics Chief Financial Officer Daniella Beckman reported new equity awards and related tax sales. On February 2, 2026, she acquired 44,330 shares of common stock for $0, representing restricted stock units that vest in three tranches through February 2029, and received a stock option for 265,980 shares at an exercise price of $11.94 per share, vesting over four years.
On February 3, 2026, she sold 10,204 and 113 shares of common stock at weighted average prices of $12.2573 and $12.8971, respectively, under the company’s automatic “sell-to-cover” policy for tax withholding tied to RSU vesting. After these transactions, she held 184,297 shares of common stock and 265,980 stock options, all reported as directly owned.
Barbara Weber, Director and Executive Chair of Tango Therapeutics, Inc., reported multiple equity transactions. She acquired 37,522 shares of common stock on February 2, 2026 through restricted stock units that vest in full on February 1, 2027, subject to continued service.
On the same date she was granted a stock option for 222,132 shares at an exercise price of $11.94 per share, vesting in 12 equal monthly installments following January 1, 2026. To satisfy tax withholding under the issuer’s sell-to-cover policy, she automatically sold 30,186 shares at a weighted average price of $12.2573 and 333 shares at $12.8971 on February 3, 2026. After these transactions, she directly owned 1,629,254 shares of common stock and 222,132 options.
Tango Therapeutics President of R&D Crystal Adam reported new equity awards and related tax sales of common stock. On February 2, 2026, she received 47,460 restricted stock units, each equal to one share, vesting 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to continued service. She also received a stock option for 284,760 shares at an exercise price of $11.94, vesting 25% on January 1, 2027 and monthly thereafter for three years. To cover tax withholding from RSU vesting under the company’s sell-to-cover policy, she automatically sold 18,251 shares at a weighted average $12.2573 and 201 shares at a weighted average $12.8971 on February 3, 2026. After these transactions, she directly owned 187,218 common shares and 284,760 options.
Tango Therapeutics, Inc. reported that President & CEO and director Malte Peters received new equity awards. On January 8, 2026, he was granted 350,000 restricted stock units (RSUs) of common stock at a grant price of $0.00, increasing his directly held common shares to 367,500. Each RSU represents one share of common stock and will vest over three years: 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to continued service.
He was also granted a stock option for 1,650,000 shares of common stock with an exercise price of $11.06 per share, expiring on January 8, 2036. This option vests over four years, with 25% vesting on January 8, 2027 and the remainder vesting in 36 substantially equal monthly installments thereafter, contingent on continued service, leaving him with 1,650,000 options beneficially owned.
Tango Therapeutics (TNGX) reported a director’s Form 4 reflecting a grant of stock options for 150,000 shares at an exercise price of $8.01 on November 3, 2025.
The options expire on November 3, 2035 and vest in 48 substantially equal monthly installments over four years, with the first vesting date on December 3, 2025, subject to continuous service. After this transaction, the reporting person directly holds 150,000 derivative securities.
Tango Therapeutics (TNGX): Third Rock Ventures IV, L.P. reported an open-market sale of common stock. On 10/23/2025, the reporting person sold 477,401 shares (Transaction Code S) at a weighted average price of $10.152, with individual trades executed between $10.00 and $10.65.
Following the sale, the filing reports 13,386,574 shares beneficially owned. The shares are directly held by Third Rock Ventures IV, L.P.; affiliated general partners are listed and disclaim beneficial ownership except to the extent of any pecuniary interest.
Third Rock Ventures IV, L.P. reported a sale of 500,000 shares of Tango Therapeutics, Inc. (TNGX) executed on 09/25/2025 at a weighted-average price of $8.017 per share. After the sale, the reporting person holds 13,863,975 shares, which are directly held by Third Rock Ventures IV, L.P. The filing identifies Third Rock Ventures GP IV, L.P. and TRV GP IV, LLC as related entities that disclaim beneficial ownership except to the extent of any pecuniary interest. The form was signed by Kevin Gillis on 09/29/2025.
Third Rock Ventures entities reported an insider sale of Tango Therapeutics (TNGX) common stock. On 09/16/2025 the reporting persons sold 363,541 shares at a weighted-average price of $7.04 per share (sales ranged $7.00–$7.19). After the sale, Third Rock Ventures IV, L.P. directly held 14,363,975 shares. The filing identifies the reporting parties as a director and a greater-than-10% owner and includes standard GP disclaimers that the GP entities disclaim beneficial ownership except to the extent of pecuniary interest. The Form 4 was signed by Kevin Gillis on 09/17/2025.